戻る Agendas
CHINA: OPPORTUNITIES AND CHALLENGES FOR INNOVATION
Session Chair(s)
Joseph Scheeren, PHARMD
Founder
Scheeren HealthCare LLC, United States
China has very complicated and dynamic regulatory policies in driving the development of innovative new drugs. The session will elaborate on these key regulatory policies and share experience on the regulatory aspirations, barriers and opportunities that will impact global drug development and availability of new medicines in China. How to optimize implementing innovations within such an environment requires strategic considerations, which this session aims to enlighten.
Learning Objective : Aim of the session is to enlighten on global drug development strategies in Asia within a diverse and dynamic regulatory landscape. Participants will be provided with insights from 3 speakers (industry, CIRS, former CFDA)
Speaker(s)
Understanding Regulatory Laws and Policies
Shaoyu Chen, JD
Covington & Burling LLP, China
Managing Director, China Food and Drug Practice; Partner
Quantifying the Chinese Regulatory Environment: Challenges and Opportunities
Neil McAuslane, PHD, MSC
Centre for Innovation in Regulatory Science (CIRS), United Kingdom
Scientific Director
An Overview of the Drug Development Landscape in China
Amar Kureishi
Quintiles, Singapore
VP and Regional Chief Medical Officer